Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care

Learn more about:
Related Clinical Trial
Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Icotinib for Completed Resected IB NSCLC With EGFR Mutation Circulating Tumor DNA in Patients at High Risk for Lung Cancer Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery QUILT-3.017: Study of NEO-201 in Solid Tumors Photodynamic Therapy in Treating Patients With Lung Cancer Vaccine Treatment for Advanced Non-Small Cell Lung Cancer S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC The Tracking Molecular Evolution for NSCLC (T-MENC) Study Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) P2 of RMT in Combo w Durvalumab or Durva + Chemo in Untreated Adenocarcinoma NSCLC Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma Prospective Radiological Study of HRCT to Predict Pathological Noninvasiveness in NSCLC To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung Lung Cancer Mutation Consortium Protocol The Detection of EGFR Mutations in Liquid Based Cytology Samples NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR Telomere Biology in Early Adenocarcinoma of the Lung

Brief Title

Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care

Official Title

Adherence to NCCN Survivorship Care Guidelines in Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care

Brief Summary

      This clinical trial studies adherence to survivorship care guidelines in health care
      providers for non-small cell lung cancer or colorectal cancer survivor care. The completion
      of an educational intervention by health care providers may increase compliance and adherence
      to National Comprehensive Cancer Network guidelines for survivorship care.
    

Detailed Description

      PRIMARY OBJECTIVES:

      I. To evaluate adherence of oncology health care providers to National Comprehensive Cancer
      Network (NCCN) guidelines for cancer survivorship care in colorectal cancer (CRC) and
      non-small cell lung cancer (NSCLC) cancers.

      SECONDARY OBJECTIVES:

      I. To develop and assess a targeted educational initiative to improve compliance with NCCN
      CRC and NSCLC survivorship guidelines for oncology health care providers in academic and
      community practice.

      II. To evaluate the impact of this educational initiative on documented adherence and
      compliance with NCCN guidelines for NSCLC and CRC survivorship care by oncology health care
      providers.

      OUTLINE:

      Health care providers complete an educational intervention based on NCCN guidelines in CRC
      and NSCLC survivorship care comprising a power point presentation reviewing evidence and
      guidelines; a USB drive of the NCCN guidelines with paper copy of pages addressing
      survivorship care; an electronic and paper copy of a sample survivorship clinic template note
      with prompts for addressing survivorship care components; and an electronic paper copy sample
      survivorship care plan that can be adapted and distributed at each participating site.
    


Study Type

Interventional


Primary Outcome

Percentage of eligible CRC and NSCLC survivors with medical record documentation of compliance with NCCN guidelines

Secondary Outcome

 Change in percentage of eligible survivors with documentation of compliance with NCCN survivorship guidelines after conducting the targeted educational initiative at participating sites

Condition

Adenocarcinoma of the Lung

Intervention

educational intervention

Study Arms / Comparison Groups

 Health services research (educational intervention)
Description:  Health care providers complete an educational intervention based on NCCN guidelines in CRC and NSCLC survivorship care comprising a power point presentation reviewing evidence and prompts for addressing survivorship care components; and an electronic paper copy sample survivorship care plan that can be adapted and distributed at each participating site.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

1440

Start Date

January 2013

Completion Date

July 2015

Primary Completion Date

July 2015

Eligibility Criteria

        Inclusion Criteria:

          -  HEALTH CARE PROVIDER INCLUSION CRITERIA:

          -  Any health care provider (physician, advanced practice clinician) at a study site (Fox
             Chase Cancer Center [FCCC] and Fox Chase Cancer Center Partners [FCCCP]) who provides
             care for NSCLC and/or CRC survivors

          -  CHART AUDIT INCLUSION CRITERIA (BASELINE):

          -  Cancer Registry cases include stage I-III colon cancer (adenocarcinoma histology),
             stage I-III rectal cancer (adenocarcinoma histology), stage I-III non-small cell lung
             cancer (squamous or adenocarcinoma histology)

          -  Patients must have completed all therapy for curative intent at least six months prior
             to chart audit

          -  Undergoing routine oncology care and surveillance at the chosen site (defined as
             receiving follow-up care with FCCC or FCCCP site health care providers and have an
             active medical chart)

          -  No evidence of metastatic disease

          -  Patients must have been seen for a visit for cancer surveillance between 2009 and 2013

          -  Health care providers at the participating site must be willing and able to
             participate in the educational initiative

          -  CHART AUDIT INCLUSION CRITERIA (POST-INTERVENTION)

          -  Charts eligible for audit after completion of the educational initiative will be for
             those CRC and NSCLC survivors presenting for follow-up after the initiative has been
             completed by site health care providers

        Exclusion Criteria:

          -  CHART AUDIT EXCLUSION CRITERIA:

          -  Cancer Registry cases for diseases other than colon or rectal adenocarcinoma and
             non-small cell lung cancer (squamous or adenocarcinoma histology)

          -  Patients currently receiving active therapy for any cancer, including CRC or NSCLC

          -  Patients who do not undergo routine oncologic care at the chosen Partners site or Fox
             Chase Cancer Center

          -  Stage IV cancer or evidence of metastatic disease at any time point

          -  Patients who have not undergone a visit for cancer surveillance since 2009

          -  Fox Chase Cancer Partners sites who do not agree to chart audit procedures or
             providers are unable or unwilling to participate in the educational initiative
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Crystal Denlinger, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01726296

Organization ID

12-841

Secondary IDs

NCI-2012-01717

Responsible Party

Sponsor

Study Sponsor

Fox Chase Cancer Center


Study Sponsor

Crystal Denlinger, MD, Principal Investigator, Fox Chase Cancer Center


Verification Date

November 2016